-
Ovarian Cancer Drugs Market to Hit $7.2 Billion by 2035, Driven by Rising FDA Approvals and 2024's $4.2 Billion Base
14 Jul 2025 07:02 GMT
… Drugs Market grows as FDA, EMA fast-track advanced … 2025, Biocon Biologics gained FDA approval for Jobevne (bevacizumab … • In April 2024, the FDA granted full approval to mirvetuximab … trial, in partnership with Daiichi Sankyo, follows encouraging phase I …
-
Pledging ‘Radical Transparency,’ FDA Reveals Drug Rejection Letters — With Limits
13 Jul 2025 18:50 GMT
… , developed by partners AstraZeneca and Daiichi Sankyo, targets the cancer protein TROP2 … counteract adverse liver effects.
—The FDA turned down Stealth Biotherapeutics application … quarter 2025 start.
Other FDA Actions
—The FDA eased some restrictions for …
-
FDA Publishes Cache of Complete Response Letters in Bid for ‘Radical Transparency’
10 Jul 2025 16:54 GMT
… transparency,” according to the FDA’s announcement. The Complete … efficacy concerns from the FDA when announcing that their … chewable gum version of Daiichi Sankyo’s cholesterol medication Welchol … site in Mississippi.
The FDA under President Donald Trump …
-
Insights From ASCO 2025 Guide Pharmacy Practice in Solid Tumors and Hematologic Cancers
16 Jul 2025 17:16 GMT
… trial findings, leading to an FDA approval in 2024, but challenges … only intravenous trastuzumab-deruxtecan (Enhertu; Daiichi Sankyo, AstraZeneca) currently approved for HER2 …
-
Menin Inhibitors Market Forecasts Signal Strong Uptake of Menin Inhibitors in Hematologic Oncology Across the 7MM During the Forecast Period (2020-2034) | DelveInsight
16 Jul 2025 01:57 GMT
… 2A (KMT2A) gene. The FDA approved this drug in November … studies.
In April 2024, the FDA granted ziftomenib breakthrough therapy designation … Astellas Pharma, Pfizer, Novartis Oncology, Daiichi Sankyo, Chimerix, Takeda, Rafael Pharmaceuticals Inc …
-
Endometrial Cancer Clinical Trial Pipeline Insights: 50+ Companies Shaping Future Treatment Paradigms | DelveInsight
15 Jul 2025 17:00 GMT
… clinical trials.
In June 2025, Daiichi Sankyo announced the first patient had … , Acrivon Therapeutics announced that the FDA had granted Breakthrough Device Designation …
-
Non-Small Cell Lung Cancer Market: Valued at $18.8 Billion in 2024, Expected to Grow at 6.9% CAGR Through 2035
15 Jul 2025 07:59 GMT
… April 2025, Biocon Biologics received FDA approval for Jobevne (bevacizumab-nwgd … approved by the U.S. FDA to treat adult patients with … that the U.S. FDA had approved Optune Lua to … GmbH
• Bristol Myers Squibb Co.
• DAIICHI SANKYO CO. LTD.
• Eli Lilly and …
-
Pexidartinib Elicits Sustained Benefit in Tenosynovial Giant Cell Tumors
10 Jul 2025 23:44 GMT
… [pexidartinib], the first FDA-approved systemic therapy for … earlier findings.”
The FDA previously approved pexidartinib for … US Medical Affairs at Daiichi Sankyo, the developer of pexidartinib … .com/2e7awksp
FDA approves pexidartinib for tenosynovial …
-
Comprehensive Lewy Body Dementia Market Analysis of Evolving Trends and Anticipated Growth Trajectory During the Forecast Period (2025-2034) | DelveInsight
11 Jul 2025 00:14 GMT
… Track designation (FTD) by the FDA for the treatment of dementia … Lilly and Company, Novartis AG, DAIICHI SANKYO COMPANY, LIMITED, AbbVie Inc., Lundbeck …
-
Final ENLIVEN Trial Results Confirm Long-Term Benefit of Turalio in Tenosynovial Giant Cell Tumor
09 Jul 2025 20:47 GMT
… president, US medical affairs, Daiichi Sankyo, added: “The final results … this treatment.”
Initial FDA approval supported by early … -3-Trial
2. FDA approves pexidartinib for tenosynovial … -approved-drugs/fda-approves-pexidartinib-tenosynovial-giant …
About
© 1995-2025